Table 1 Baseline characteristics of the study population and subgroup of general health examination participants
From: Mid- and long-term risk of atrial fibrillation among breast cancer surgery survivors
| Â | Breast cancer | |
|---|---|---|
|  | No (N = 566,160) | Yes (N = 113,232) |
Age at baseline, mean (SD), years | 51.6 (10.8) | 51.6 (10.8) |
Age group, years | ||
 18–39 | 61,325 (10.8) | 12,265 (10.8) |
 40–50 | 202,435 (35.8) | 40,487 (35.8) |
 51–65 | 235,670 (41.6) | 47,134 (41.6) |
 ≥ 66 | 66,730 (11.8) | 13,346 (11.8) |
Comorbidity | ||
 Hypertension | 122,631 (21.7) | 28,779 (25.4) |
 Type 2 diabetes | 39,756 (7.0) | 10,027 (8.9) |
 Dyslipidemia | 100,734 (17.8) | 23,068 (20.4) |
 Coronary heart disease | 33,511 (5.9) | 8732 (7.7) |
 Congestive heart failure | 7670 (1.4) | 3046 (2.7) |
 Stroke | 12,177 (2.2) | 2464 (2.2) |
 Chronic kidney disease | 4444 (0.8) | 1285 (1.1) |
 Chronic obstructive pulmonary disease | 53,517 (9.5) | 20,698 (18.3) |
 Charlson comorbidity index, mean (SD) | 0.9 (1.2) | 2.5 (1.3) |
Cancer treatment type | ||
 Chemotherapy, Yes |  | 69,056 (61.0) |
  Anthracyclines |  | 58,709 (85.0) |
  Cyclophosphamide |  | 65,140 (94.3) |
  Fluorouracil |  | 15,801 (22.9) |
  Taxane |  | 36,417 (52.7) |
  Othersa |  | 7937 (11.5) |
 Trastuzumab, Yes |  | 16,945 (15.0) |
 Endocrine therapy, Yes |  | 77,925 (61.8) |
  Tamoxifen |  | 49,574 (43.8) |
  Aromatase inhibitors |  | 27,046 (23.9) |
  Both |  | 1305 (1.2) |
 Radiation therapy, Yes |  | 79,076 (69.8) |
Income status, Low | 140,488 (24.8) | 25,507 (22.5) |
Residential location, Urban | 265,234 (46.8) | 56,703 (50.1) |
General health examination participants | No (N = 292,468) | Yes (N = 72,560) |
Smoking, Ever | 14,835 (5.1) | 4216 (5.8) |
Alcohol consumption (≥ 10 g), Yes | 70,695 (24.2) | 17,531 (24.2) |
Regular physical activityb, Yes | 54,062 (18.5) | 13,330 (18.4) |
Body mass index, mean (SD), kg/m2 | 23.6 (3.3) | 23.6 (3.4) |
Obesity (BMI ≥ 25 kg/m2) | 86,548 (29.6) | 22,264 (30.7) |